The Aldose Reductase pipeline drugs market research report outlays comprehensive information on the Aldose Reductase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Aldose Reductase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, Central Nervous System, Infectious Disease, and Respiratory which include the indications Congenital Disorder of Glycosylation Type I A, Galactosemia, Diabetic Peripheral Neuropathy, Coronavirus Disease 2019 (COVID-19), and Pulmonary Inflammation. It also reviews key players involved in Aldose Reductase targeted therapeutics development with respective active and dormant or discontinued products.
The Aldose Reductase pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical, and Discovery stages are 3, 1, 1, and 1 respectively.
Aldose Reductase overview
Aldose Reductase is an enzyme that in humans is encoded by a gene AKR1B1. This is a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. Plays a role in detoxifying dietary and lipid-derived unsaturated carbonyls. This member catalyzes the reduction of several aldehydes, including the aldehyde form of glucose, and is thereby implicated in the development of diabetic complications by catalyzing the reduction of glucose to sorbitol.
For a complete picture of Aldose Reductase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
